← 홈

난소암

353개 · ADC 1068 · Antibody 5456 · CGT 2744 · 다음 갱신 D-13 · 마지막 7월 13일

인기최근 업데이트큐레이션임상 많은갱신 필요ORR최신Phase 3FDA승인프로그램 353개
AntibodyPfizerApproved

Elranatamab (Elranatamab)

Multiple Myeloma · FRα

#FR#Antibody#Approved#인기#항체+5
효능 ORR 61%임상시험 54상태 RECRUITING
ADCBiologicFondazione per la Medicina Pers…calicheamicin-based antibod…Phase 2

Ponatinib (Ponatinib)

Breast Cancer; Gastrointestinal Cancer · FRα

#FR#ADC#Phase2#인기#항체약물접합체+5
효능 ORR 7.1%임상시험 54상태 ACTIVE
CGTBiologicKitevedotin plus bendamustine a…Approved

axicabtagene ciloleucel (Yescarta, axi-cel)

Large B-cell Lymphoma; Lymphoma, B-Cell · FRα

#FR#CGT#Approved#인기#세포유전치료+5
효능 ORR 92%임상시험 53상태 RECRUITING
ADCBiologicGilead Sciencesderuxtecan (OR 4Phase 3

Idelalisib (Idelalisib)

Chronic Lymphocytic Leukaemia · FRα

#FR#ADC#Phase3#인기#항체약물접합체+5
효능 ORR 90.9%임상시험 53상태 DISCONTINUED
ADCBiologicUNICANCERPhase 2

Copanlisib (Copanlisib)

Carcinoma, Squamous Cell of Head and Neck · FRα

#FR#ADC#Phase2#인기#항체약물접합체+5
효능 ORR 100%임상시험 51상태 DISCONTINUED
AntibodyPfizerPhase 2

PF-06863135 (Elranatamab, Elranatamab (PF-06863135))

Multiple Myeloma · FRα

#FR#Antibody#Phase2#인기#항체+5
효능 ORR 61%임상시험 51상태 ACTIVE
ADCBiologicAstraZenecaderuxtecan or sacituzumab g…Phase 2

Capivasertib (Capivasertib)

Metastatic Breast Cancer · FRα

#FR#ADC#Phase2#인기#항체약물접합체+5
효능 ORR 56.5%임상시험 50상태 RECRUITING
AntibodyEpizyme, Inc.vedotin in patients with re…Phase 3

Mosunetuzumab (Mosunetuzumab)

Relapsed Hematologic Malignancy; Refractory Hematologic Malignancy · FRα

#FR#Antibody#Phase3#항체#면역항체+5
효능 ORR 87.5%임상시험 49상태 RECRUITING
ADCBiologicMedImmune LLCvedotin combined with cispl…Phase 2

DHAP (DHAP)

Diffuse Large B-Cell Lymphoma · FRα

#FR#ADC#Phase2#항체약물접합체#antibody-drug-conjugate+4
효능 ORR 47.5%임상시험 48상태 ACTIVE
ADCBiologicPfizerPhase 3

Iberdomide (Iberdomide)

Multiple Myeloma · FRα

#FR#ADC#Phase3#항체약물접합체#antibody-drug-conjugate+3
효능 ORR 92.9%임상시험 47상태 RECRUITING
ADCBiologicPfizerderuxtecan showed encouragi…Phase 1

Dacomitinib (Dacomitinib)

Non-Small Cell Lung Cancer · FRα

#FR#ADC#Phase1#항체약물접합체#antibody-drug-conjugate+4
효능 ORR 75.3%임상시험 46상태 DISCONTINUED
CGTBiologicHistograft Co., Ltd.operatedPreclinical

"Histograft", a bone substitute based on octacalcium phosphate (OCP, "Histograft", a bone substitute based on octacalcium phosphate, "Histograft", a bone substitute based on octacalcium phosphate (OCP) and plasmid DNA encoding VEGFA gene)

Non Union Fracture; Non-Union of Ankle Joint Without Infection · FRα

#FR#CGT#Preclinical#세포유전치료#CAR-T+5
임상시험 45상태 ACTIVE
ADCBiologicCanadian Cancer Trials Groupvedotin, a monoclonal antib…Phase 2

Adavosertib (Adavosertib)

Prostate Cancer · FRα

#FR#ADC#Phase2#항체약물접합체#antibody-drug-conjugate+3
효능 ORR 66.7%임상시험 45상태 RECRUITING
CGTBiologicSecuraBio-deliveringPhase 3

Duvelisib (Duvelisib)

Indolent Non-Hodgkin's Lymphoma; Follicular Lymphoma · FRα

#FR#CGT#Phase3#세포유전치료#CAR-T+5
효능 ORR 82%임상시험 45상태 RECRUITING
CGTBiologicNovartisPhase 3

tisagenlecleucel (Kymriah, tisa-cel)

Acute Lymphoblastic Leukemia · FRα

#FR#CGT#Phase3#세포유전치료#CAR-T+4
효능 ORR 83.3%임상시험 45상태 DISCONTINUED
ADCBiologicSuzhou Suncadia Biopharmaceutic…Vedotin in Transplant-Ineli…Phase 2

R-GemOx (R-GemOx)

Relapsed and Refractory DLBCL · FRα

#FR#ADC#Phase2#항체약물접합체#antibody-drug-conjugate+4
효능 ORR 69.7%임상시험 43상태 RECRUITING
CGTBiologicOHSU Knight Cancer InstitutePhase 2

Hyper-CVAD (Hyper-CVAD)

Relapsed/Refractory; B-cell Acute Lymphocytic Leukemia · FRα

#FR#CGT#Phase2#세포유전치료#CAR-T+5
효능 ORR 89%임상시험 40상태 RECRUITING
AntibodyJanssenPhase 3

Talquetamab (Talquetamab)

Myeloma Multiple; Plasma Cell Leukemia · FRα

#FR#Antibody#Phase3#항체#면역항체+5
임상시험 40상태 DISCONTINUED
CGTBiologiciCell Gene TherapeuticsPhase 1

CD4 CAR T cells (CD4 CAR T cells)

T Cell Lymphoma in Relapse; Refractory T-Cell Lymphoma · FRα

#FR#CGT#Phase1#세포유전치료#CAR-T+5
효능 ORR 80.3%임상시험 39상태 ACTIVE
AntibodyRegeneron PharmaceuticalsPhase 2

Fianlimab (Fianlimab)

Ovarian Cancer; Fallopian Tube Cancer · NSCLC

#NSCLC#Antibody#Phase2#항체#면역항체+5
임상시험 39상태 RECRUITING

3 / 18 페이지

← 이전다음 →